Cingulate 将来の成長

Future 基準チェック /06

Cingulateは、46.8%と68.5%でそれぞれ年率46.8%で利益と収益が成長すると予測される一方、EPSはgrowで77.8%年率。

主要情報

46.8%

収益成長率

77.8%

EPS成長率

Pharmaceuticals 収益成長	23.9%
収益成長率	68.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 Nov 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Aug 26

Cingulate Q2 GAAP EPS of -$0.36

Aug 11

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Apr 04

業績と収益の成長予測

NasdaqCM:CING - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4	-7	N/A	N/A	2
12/31/2025	N/A	-13	N/A	-14	3
12/31/2024	N/A	-13	N/A	-12	3
9/30/2024	N/A	-16	-17	-17	N/A
6/30/2024	N/A	-19	-18	-17	N/A
3/31/2024	N/A	-23	-20	-20	N/A
12/31/2023	N/A	-24	-15	-15	N/A
9/30/2023	N/A	-21	-17	-17	N/A
6/30/2023	N/A	-19	-16	-16	N/A
3/31/2023	N/A	-17	-16	-16	N/A
12/31/2022	N/A	-18	-16	-16	N/A
9/30/2022	N/A	-16	-17	-16	N/A
6/30/2022	N/A	-27	-16	-15	N/A
3/31/2022	N/A	-24	-13	-13	N/A
12/31/2021	N/A	-21	-11	-10	N/A
9/30/2021	N/A	-19	-8	-8	N/A
6/30/2021	N/A	-5	-7	-7	N/A
3/31/2021	N/A	-6	-7	-7	N/A
12/31/2020	N/A	-7	-7	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CING今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CING今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CING今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CING来年は収益がないと予測されています。

高い収益成長: CING来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CINGの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cingulate 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2025

No longer forecast to breakeven

Recent updates

The Nasdaq Hearings Panel Grants Cingulate's Request for an Exception to Demonstrate Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing Through August 23, 2024

Cingulate Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

Cingulate Inc., Annual General Meeting, Jun 11, 2024

Cingulate Inc. Regains Compliance with the Board Composition Requirements of Nasdaq Set in Nasdaq Listing Rule 5605

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. Announces Promotion of Jennifer Callahan as Chief Financial Officer

Cingulate Inc. has filed a Follow-on Equity Offering in the amount of $26 million.

Cingulate Receives Non-Compliance Notice from Nasdaq

Cingulate Inc. and Cingulate Therapeutics LLC Announce Resignation of Officer

Scott Applebaum Provides Cingulate Inc. with Notice of His Resignation from the Board of Directors

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTX-2103 (Buspirone)

Cingulate Inc. has filed a Follow-on Equity Offering.

The Listing Qualifications Staff of The Nasdaq Stock Market LLC Determines to Delist Cingulate's Securities from Nasdaq Unless it Timely Requests Hearing Before the Nasdaq Hearings Panel

Cingulate Inc. to Host CNS Key Opinion Leader Panel in New York City Expert Analysis of Cingulate, it’s Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations

Cingulate Weighs Reverse Stock Split to Avoid Delisting

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $4 million.

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Cingulate Inc. Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Cingulate Inc. Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for Adhd

Cingulate Inc. Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August

New major risk - Market cap size

Cingulate Completes Phase 3 Adult Trial of Ctx-1301 (Dexmethylphenidate) for Adhd

Cingulate Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

Cingulate Inc., Annual General Meeting, Jun 15, 2023

Forecast to breakeven in 2025

No longer forecast to breakeven

Cingulate Inc. Announces Resignation of Jeff Conroy from the Board of Directors

Cingulate Inc. Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Independent Director recently bought US$75k worth of stock

Cingulate Inc. Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Cingulate Inc. Provides Clinical Update

Cingulate Inc. Announces the Resignation of Jeff Hargroves from the Board of Directors

Cingulate Presents Data for its Triple-Release Buspirone Product Candidate: CTx-2103

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Cingulate Inc. Appoints Scott Applebaum as Class III Director

Cingulate Q2 GAAP EPS of -$0.36

Cingulate Inc. Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

Cingulate Inc. Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Cingulate Inc. Announces First Subject Dosing in its Human Formulation Study of CTX-2103 (Buspirone) for the Treatment of Anxiety

Cingulate Inc., Annual General Meeting, Jun 08, 2022

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$89k worth of stock

Cingulate Inc Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘